FI4185318T3 - Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon - Google Patents
Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoonInfo
- Publication number
- FI4185318T3 FI4185318T3 FIEP22728724.0T FI22728724T FI4185318T3 FI 4185318 T3 FI4185318 T3 FI 4185318T3 FI 22728724 T FI22728724 T FI 22728724T FI 4185318 T3 FI4185318 T3 FI 4185318T3
- Authority
- FI
- Finland
- Prior art keywords
- aflibercept
- weeks
- week
- initial dose
- micrometers
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
- A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Ophthalmology & Optometry (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163189541P | 2021-05-17 | 2021-05-17 | |
| US202163235398P | 2021-08-20 | 2021-08-20 | |
| US202263297420P | 2022-01-07 | 2022-01-07 | |
| US202263306315P | 2022-02-03 | 2022-02-03 | |
| PCT/US2022/029462 WO2022245739A1 (en) | 2021-05-17 | 2022-05-16 | Extended, high dose vegf antagonist regimens for treatment of angiogenic eye disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI4185318T3 true FI4185318T3 (fi) | 2025-10-13 |
Family
ID=81975181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP22728724.0T FI4185318T3 (fi) | 2021-05-17 | 2022-05-16 | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20230302085A1 (https=) |
| EP (2) | EP4647125A3 (https=) |
| JP (1) | JP2024519629A (https=) |
| KR (1) | KR20240008821A (https=) |
| AU (2) | AU2022275786C1 (https=) |
| BR (1) | BR112023023002A2 (https=) |
| CA (1) | CA3190663A1 (https=) |
| CL (3) | CL2023003396A1 (https=) |
| DK (1) | DK4185318T3 (https=) |
| ES (1) | ES3041647T3 (https=) |
| FI (1) | FI4185318T3 (https=) |
| HR (1) | HRP20251282T8 (https=) |
| IL (1) | IL308505A (https=) |
| JO (1) | JOP20230283A1 (https=) |
| LT (1) | LT4185318T (https=) |
| MX (1) | MX2023013554A (https=) |
| PE (1) | PE20240922A1 (https=) |
| PL (1) | PL4185318T3 (https=) |
| PT (1) | PT4185318T (https=) |
| RS (1) | RS67369B1 (https=) |
| SI (1) | SI4185318T1 (https=) |
| TW (1) | TW202313095A (https=) |
| WO (1) | WO2022245739A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK4364724T3 (da) | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| IL315347A (en) * | 2022-03-15 | 2024-11-01 | Regeneron Pharma | Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders |
| IL315374A (en) * | 2022-03-15 | 2024-11-01 | Regeneron Pharma | Prolonged high-dose VEGF antagonist regimens for the treatment of angiogenic ocular disorders |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| CN121712520A (zh) * | 2023-06-23 | 2026-03-20 | 瑞泽恩制药公司 | 用于治疗血管生成性眼病的延长的高剂量vegf拮抗剂方案 |
| US20260055171A1 (en) | 2024-06-11 | 2026-02-26 | Regeneron Pharmaceuticals, Inc. | Vegf antagonists and methods of use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5288931A (en) * | 1991-12-06 | 1994-02-22 | Genentech, Inc. | Method for refolding insoluble, misfolded insulin-like growth factor-I into an active conformation |
| GB9912350D0 (en) * | 1999-05-26 | 1999-07-28 | European Molecular Biology Lab Embl | Modified cytokine |
| US7396664B2 (en) | 1999-06-08 | 2008-07-08 | Regeneron Pharmaceuticals, Inc. | VEGF-binding fusion proteins and nucleic acids encoding the same |
| FI117667B (fi) * | 2001-07-05 | 2007-01-15 | Univ Zuerich | Farmaseuttinen koostumus, joka soveltuu käytettäväksi ortopediassa ja hammaslääketieteessä |
| AR046510A1 (es) | 2003-07-25 | 2005-12-14 | Regeneron Pharma | Composicion de un antagonista de vegf y un agente anti-proliferativo |
| EP1767546B1 (en) | 2004-06-08 | 2012-03-07 | Chengdu Kanghong Biotechnologies Co., Ltd. | Angiogenesis-inhibiting chimeric protein and the use |
| CN100502945C (zh) | 2006-03-31 | 2009-06-24 | 成都康弘生物科技有限公司 | Vegf受体融合蛋白在治疗眼睛疾病中的应用 |
| KR20190049934A (ko) * | 2011-01-13 | 2019-05-09 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| AU2012212047A1 (en) * | 2011-02-03 | 2013-08-22 | Xoma Technology Ltd. | Methods and materials for enhancing functional protein expression in bacteria |
| TWI806150B (zh) * | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| CA3010862A1 (en) * | 2016-01-08 | 2017-07-13 | Clearside Biomedical, Inc. | Methods and devices for treating posterior ocular disorderswith aflibercept and other biologics |
| HUE059827T2 (hu) * | 2017-11-30 | 2023-01-28 | Regeneron Pharma | VEGF-antagonista alkalmazása angiogén szembetegségek kezelésére |
| CN117138171A (zh) | 2017-12-13 | 2023-12-01 | 里珍纳龙药品有限公司 | 用于精确剂量输送的装置和方法 |
| DK4364724T3 (da) * | 2018-05-10 | 2025-12-22 | Regeneron Pharma | Formuleringer med høj koncentration af VEGF-receptorfusionsprotein |
| EP3886946A1 (en) | 2019-06-05 | 2021-10-06 | Regeneron Pharmaceuticals, Inc. | Devices and methods for precision dose delivery |
| US20220306732A1 (en) * | 2019-09-12 | 2022-09-29 | Lupin Limited | Modified dosing of vegf inhibitors for ophthalmic use |
-
2022
- 2022-05-16 KR KR1020237013896A patent/KR20240008821A/ko active Pending
- 2022-05-16 IL IL308505A patent/IL308505A/en unknown
- 2022-05-16 US US18/021,802 patent/US20230302085A1/en active Pending
- 2022-05-16 JP JP2023513604A patent/JP2024519629A/ja active Pending
- 2022-05-16 TW TW111118217A patent/TW202313095A/zh unknown
- 2022-05-16 MX MX2023013554A patent/MX2023013554A/es unknown
- 2022-05-16 BR BR112023023002A patent/BR112023023002A2/pt unknown
- 2022-05-16 EP EP25189523.1A patent/EP4647125A3/en active Pending
- 2022-05-16 PE PE2023003023A patent/PE20240922A1/es unknown
- 2022-05-16 PT PT227287240T patent/PT4185318T/pt unknown
- 2022-05-16 ES ES22728724T patent/ES3041647T3/es active Active
- 2022-05-16 EP EP22728724.0A patent/EP4185318B1/en active Active
- 2022-05-16 SI SI202230175T patent/SI4185318T1/sl unknown
- 2022-05-16 WO PCT/US2022/029462 patent/WO2022245739A1/en not_active Ceased
- 2022-05-16 RS RS20251029A patent/RS67369B1/sr unknown
- 2022-05-16 DK DK22728724.0T patent/DK4185318T3/da active
- 2022-05-16 CA CA3190663A patent/CA3190663A1/en active Pending
- 2022-05-16 AU AU2022275786A patent/AU2022275786C1/en active Active
- 2022-05-16 LT LTEPPCT/US2022/029462T patent/LT4185318T/lt unknown
- 2022-05-16 HR HRP20251282TT patent/HRP20251282T8/hr unknown
- 2022-05-16 PL PL22728724.0T patent/PL4185318T3/pl unknown
- 2022-05-16 FI FIEP22728724.0T patent/FI4185318T3/fi active
-
2023
- 2023-11-06 JO JOJO/P/2023/0283A patent/JOP20230283A1/ar unknown
- 2023-11-14 CL CL2023003396A patent/CL2023003396A1/es unknown
-
2024
- 2024-10-02 CL CL2024002972A patent/CL2024002972A1/es unknown
-
2025
- 2025-04-29 CL CL2025001269A patent/CL2025001269A1/es unknown
- 2025-09-04 AU AU2025226774A patent/AU2025226774A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20240008821A (ko) | 2024-01-19 |
| BR112023023002A2 (pt) | 2024-01-23 |
| AU2022275786A8 (en) | 2023-04-20 |
| AU2022275786B2 (en) | 2025-06-05 |
| EP4185318B1 (en) | 2025-09-03 |
| JOP20230283A1 (ar) | 2023-11-06 |
| HRP20251282T8 (hr) | 2025-12-19 |
| MX2023013554A (es) | 2023-11-29 |
| PT4185318T (pt) | 2025-09-29 |
| CL2025001269A1 (es) | 2025-08-22 |
| EP4647125A3 (en) | 2026-01-28 |
| EP4185318A1 (en) | 2023-05-31 |
| PE20240922A1 (es) | 2024-04-30 |
| PL4185318T3 (pl) | 2026-01-12 |
| WO2022245739A1 (en) | 2022-11-24 |
| LT4185318T (lt) | 2025-11-10 |
| DK4185318T3 (da) | 2025-09-29 |
| SI4185318T1 (sl) | 2025-10-30 |
| HRP20251282T1 (hr) | 2025-12-05 |
| CA3190663A1 (en) | 2022-11-24 |
| IL308505A (en) | 2024-01-01 |
| EP4647125A2 (en) | 2025-11-12 |
| JP2024519629A (ja) | 2024-05-21 |
| RS67369B1 (sr) | 2025-11-28 |
| AU2022275786C1 (en) | 2025-12-11 |
| CL2023003396A1 (es) | 2024-06-07 |
| ES3041647T3 (en) | 2025-11-13 |
| AU2025226774A1 (en) | 2025-09-25 |
| TW202313095A (zh) | 2023-04-01 |
| CL2024002972A1 (es) | 2025-01-24 |
| US20230302085A1 (en) | 2023-09-28 |
| AU2022275786A1 (en) | 2023-04-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI4185318T3 (fi) | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon | |
| FI4364724T3 (fi) | Korkean pitoisuuden VEGF-reseptorifuusioproteiinia sisältäviä formulaatioita | |
| CA2718161C (en) | Drug delivery to the anterior and posterior segments of the eye using eye drops | |
| JP2023071798A5 (https=) | ||
| JP2024519629A5 (https=) | ||
| JP2017061467A5 (https=) | ||
| KR102373289B1 (ko) | 지속성 부종을 갖는 삼출성 노인성 황반변성을 치료하기 위한 시롤리무스의 용도 | |
| KR20170082526A (ko) | 안 질환의 치료 방법 | |
| Boscia et al. | Intravitreal triamcinolone acetonide in refractory pseudophakic cystoid macular edema: functional and anatomic results | |
| MXPA04004363A (es) | Procedimientos para tratar enfermedades neovasculares oculares. | |
| JP2016522250A (ja) | 黄斑浮腫の治療におけるｖｅｇｆアンタゴニストの使用 | |
| Kaiser et al. | Suprachoroidal CLS-AX (axitinib injectable suspension), as a potential long-acting therapy for neovascular age-related macular degeneration (nAMD) | |
| US20070027102A1 (en) | Methods and compositions for treating macular degeneration | |
| JP7828274B2 (ja) | 眼疾患を治療するための方法 | |
| Moon et al. | Intravitreal bevacizumab for macular edema from idiopathic juxtafoveal retinal telangiectasis | |
| Tewari et al. | Prospective evaluation of intravitreal triamcinolone acetonide injection in macular edema associated with retinal vascular disorders | |
| MUNIR et al. | Visual outcome after suprachoroidal injection of triamcinolone acetate in cystoid macular edema of different pathology | |
| Khalil et al. | Comparison between the Effect of Aflibercept (Eylea) and Ranibizumab (Lucentis) on Intraocular Pressure after 3rd Injection in Treatment of Diabetic Macular Edema | |
| Augustin et al. | Suprachoroidal drug delivery–a new approach for the treatment of severe macular diseases | |
| Bakri et al. | Antiangiogenic agents: intravitreal injection | |
| Naeem et al. | Visual outcome after intravitreal bevacizumab (Avastin) in the treatment of branch retinal vein occlusion | |
| RU2394535C2 (ru) | Способ введения лекарственных препаратов в субтеноново пространство у пациентов с оперированной глаукомой | |
| Shaikh et al. | Effect of intravitreal bevacizumab in diabetic macular edema. | |
| WO2026053205A1 (en) | Means and method for suprachoroidal drug delivery to a back of an eye | |
| JP2026072102A (ja) | 眼疾患を治療するための方法 |